镇脑宁胶囊治疗脑动脉硬化症的临床疗效及经济效益学分析

将254例脑动脉硬化症患者按照就诊顺序随机分为2组,试验组128例给予镇脑宁胶囊治疗,对照组126例给予养血清脑颗粒治疗.采用双盲/平行性对照研究,疗程均为4周.观察2组疗效及不良反应,并进行药物经济学评价.探讨镇脑宁胶囊治疗脑动脉硬化症的临床疗效和安全性以及其经济学效益.研究表明镇脑宁胶囊治疗脑动脉硬化症中医证侯疗效(中医证候积分疗效、愈显率)优于对照药养血清脑颗粒,差异有统计学意义(P＜0.01),其余各项指标以及不良反应发生率差异均无统计学意义,但试验组成本效果比低于对照组(P＜0.01).镇脑宁胶囊治疗脑动脉硬化症临床疗效优于养血清脑颗粒,临床应用安全,具有更好的经济学优势.

Study on clinical efficacy of Zhennaoning capsules in treatment of cerebral arteriosclerosis and analysis on its economic benefits

To study clinical efficacy of Zhennaoning capsules in treating cases with cerebral arteriosclerosis, and analyze its economic benefits. Totally 254 cases with cerebral arteriosclerosis were randomly divided into two groups according to their doctor-consulting sequence: the test group (n=128) that was administered with Zhennaoning capsules, and the control group (n=126) that was administered with Yangxueqingnao granules. A double-blind parallel-controlled study was conducted for four weeks, in order to observe the clinical efficacy and adverse effects of the two groups, and evaluate their pharmacoeconomics. Additionally, the clinical efficacy and safety of Zhennaoning capsules in treating cerebral arteriosclerosis, as well as its pharmacoeconomics were also discussed. This study showed that Zhennaoning capsules had a better efficacy than its control drug Yangxueqingnao granules in relieving traditional Chinese medicinal syndromes (according to traditional Chinese medicinal syndrome coring, efficacy and cure rate), suggesting a statistical significance (P<0.01). Despite statistical significance showed from the differences in the remaining indexes and the occurrence rate of adverse effects, the test group displayed a lower cost effectives than the control group (P<0.01). Zhennaoning capsules have a better clinical efficacy in treating cases with cerebral arteriosclerosis than Yangxueqingnao granules, demonstrating safe clinical application and better economic advantages.